{"schema_version":"secwatch.filing_event.v1","accession":"0001613103-21-000058","form_type":"8-K","ticker":"MDT","cik":"0001613103","company_name":"Medtronic plc","filed_at":"2021-11-23T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.320093+00:00","generated_at":"2026-06-28T05:46:42.678854+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Medtronic Q2 FY2022 revenue $7.85B (+2% organic), non-GAAP EPS $1.32; lowers FY revenue growth view","bullets":["Revenue $7.847B (+3% reported, +2% organic); GAAP EPS $0.97, non-GAAP EPS $1.32.","Organic growth: Cardiovascular +3%, Medical Surgical flat (ex-ventilators +6%), Neuroscience +3%, Diabetes +1%.","Lowers FY22 organic revenue growth guidance to 7-8% from ~9% due to COVID-19 and labor shortages.","Reiterates FY22 non-GAAP EPS guidance $5.65-$5.75; FX revenue benefit reduced to $0-50M from $100-200M.","Diabetes pump sales grew high-teens US, low-twenties international; CGM sales low-single digits."],"urls":{"canonical":"https://secwatch.observer/filing/0001613103-21-000058","json":"https://secwatch.observer/filing/0001613103-21-000058.json","markdown":"https://secwatch.observer/filing/0001613103-21-000058.md","text":"https://secwatch.observer/filing/0001613103-21-000058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1613103/000161310321000058/0001613103-21-000058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1613103/000161310321000058/mdt-20211123.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T05:46:42.678854+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}